Lazertinib
- Generic Name
- Lazertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N8O3
- CAS Number
- 1903008-80-9
- Unique Ingredient Identifier
- 4A2Y23XK11
- Background
Lazertinib is under investigation in clinical trial NCT04487080 (A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05112952
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪APEX GmbH, Munchen, Germany
A Study of Lazertinib (JNJ-73841937) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05076877
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 776
- Registration Number
- NCT04988295
- Locations
- 🇳🇱
VUMC Amsterdam, Amsterdam, Netherlands
🇲🇽Instituto Nacional de Cancerologia, Mexico, Mexico
🇲🇽Oncologia Integral Satelite, Naucalpan, Mexico
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT04965090
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 159
- Registration Number
- NCT04606381
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇬🇧Royal Marsden Hospital, Sutton, United Kingdom
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1074
- Registration Number
- NCT04487080
- Locations
- 🇯🇵
National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-shi, Japan
🇯🇵National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵Wakayama Medical University Hospital, Wakayama, Japan
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04410094
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 701
- Registration Number
- NCT04077463
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸UCSF Helen Diller Comprehensive, San Francisco, California, United States
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT04075396
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Advent Health Orlando, Orlando, Florida, United States
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 751
- Registration Number
- NCT02609776
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.